|
Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone. |
|
|
Stock and Other Ownership Interests - Leuchemix |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Sanofi (Inst); Sotio (Inst) |
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination |
|
|
No Relationships to Disclose |
|
|
Employment - Fort Wayne Medical Oncology & Hematology |
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology; Lutheran hospital (I) |
Honoraria - Alexion Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly |
Consulting or Advisory Role - Alexion Pharmaceuticals; Bristol-Myers Squibb |
Speakers' Bureau - Alexion Pharmaceuticals |
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HERON (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Seagen (Inst); TG Therapeutics (Inst) |
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Bristol-Myers Squibb; Lilly |
|
|
No Relationships to Disclose |
|
|
Employment - Oregon Urology Institute |
Honoraria - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer |
Research Funding - Amgen; Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer |
|
|
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb |
Consulting or Advisory Role - Exelixis |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Janssen Oncology; Myriad Genetics; Pacific Edge Biotechnology; Urogen pharma; UROGPO |
Research Funding - Merck (Inst); Taris BioMedical (Inst) |
|
|
Employment - Compass Oncology |
Leadership - Compass Oncology |
|
|
Stock and Other Ownership Interests - Advaxis |
|
Consulting or Advisory Role - AstraZeneca |
Speakers' Bureau - Sanofi |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar |
Speakers' Bureau - Bayer; Dendreon; Janssen |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
|
|
Travel, Accommodations, Expenses - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Patent (Inst) |
|
|
|
Stock and Other Ownership Interests - Lilly |
Patents, Royalties, Other Intellectual Property - Lilly |
|
|
Employment - Lilly; Lilly; Lilly (I) |
Stock and Other Ownership Interests - Lilly; Lilly (I) |
Research Funding - Lilly; Lilly (I) |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
Travel, Accommodations, Expenses - Lilly |
|
|
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst) |
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Rgenix (Inst); Sanofi (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst) |
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical |